Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study

Cairo University (CU)

Status: Unknown

Conditions: Oral Squamous Cell Carcinoma

Treatments: Diagnostic Test: Bmi-1 antibody

Study type: Interventional

Funder types: Other

Identifiers

NCT03345966

CEBD-CU-2017-11-01

Details and patient eligibility

About

The aim of the current study is to assess the validation of Bmi-1 detection at both protein and molecular levels in oral epithelial dysplasia and oral squamous cell carcinoma as a biomarker for early cancer detection versus biopsy embedded in paraffin blocks.

Full description

Head and neck squamous cell carcinoma (HNSCC) including oral squamous cell carcinoma (OSCC) has been reported as the sixth most common cause of cancer mortality in the world and the fifth most commonly occurring cancer. Thus a compelling need for investigation of the underlying molecular events associated with OSCC tumorigenesis has emerged for better understanding of such lesion. Moreover, identification of biomarkers for early detection and prediction of prognosis became of extreme importance, as it was reported that early diagnosis has been vital for effective treatment of OSCC and improved the survival rate of OSCC patients.

OSCC may originate from malignant transformation of the normal oral mucosa, as well as from oral potentially malignant lesions (OPMLs) with different degrees of oral epithelial dysplasia (OED). The approach of a step-wise transition from OPMLs to OSCC was well-established, but it could be difficult to predict if and when an OPML would undergo full transformation and resulted in a tumor. Thus, using specific molecular biomarkers able to identify OED lesions with higher potential for malignant transformation would be very beneficial. Unfortunately, up to date there has been no tools available to monitor OED lesions or HNSCC patients for early stages of local recurrences or distant metastases .

Among the recently introduced biomarkers, B-lymphoma Moloney murine leukemia virus insertion region-1 (BMI1), a member of the polycomb group (PcG) genes, was considered to be pivotal in regulating stemness-related genes involved in maintaining the self-renewal ability of stem cells by promoting chromatin modifications. BMI1 was also known to be deregulated in various human types of cancer. Previous studies have revealed the capability of BMI1 to be used as a prognostic marker in gastric, esophageal, nasopharyngeal cancer, prostate, breast, cervical and ovarian cancer, However, the role of BMI1 in maintaining self-renewal and tumorigenicity in HNSCC or HNSCC-derived cancer stem cells (CSCs) remained to be clarified.

Enrollment: 18 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. In vitro studies.
2. Samples used are oral dysplasia and squamous cell carcinoma.
3. Diagnostic accuracy of Bmi-1 marker on oral dysplasia and SCC.
4. English language published articles only.

Exclusion criteria

1. In vivo studies.
2. Studies using any techniques other than immunohistochemistry or PCR.
3. Samples using any carcinoma rather than squamous cell carcinoma.
4. Samples using benign tumors.
5. Samples using sarcomas.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

18 participants in 2 patient groups

Immunohistochemistry

Experimental group

Description:

In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used. The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units.

Treatment:

Diagnostic Test: Bmi-1 antibody

Polymerase Chain Reaction PCR

Experimental group

Description:

Calculation of Relative Quantification (RQ) (relative expression): After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows: Finally, RQ was calculated according to the following equation: 1. ∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene 2. ∆∆ Ct = ∆ Ct sample - Ct control gene 3. RQ = 2-(∆∆Ct)

Treatment:

Diagnostic Test: Bmi-1 antibody